Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Cut by DSM Capital Partners LLC

DSM Capital Partners LLC lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,222,009 shares of the company’s stock after selling 2,008 shares during the period. Neurocrine Biosciences makes up 2.5% of DSM Capital Partners LLC’s holdings, making the stock its 15th largest position. DSM Capital Partners LLC owned approximately 1.24% of Neurocrine Biosciences worth $161,012,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Brown Advisory Inc. boosted its holdings in shares of Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after acquiring an additional 23,831 shares in the last quarter. Braidwell LP lifted its holdings in shares of Neurocrine Biosciences by 3.7% in the third quarter. Braidwell LP now owns 968,024 shares of the company’s stock valued at $108,903,000 after buying an additional 34,662 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after buying an additional 364,986 shares during the period. Jacobs Levy Equity Management Inc. boosted its stake in Neurocrine Biosciences by 59.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after buying an additional 256,920 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Neurocrine Biosciences by 10.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 686,835 shares of the company’s stock worth $90,497,000 after acquiring an additional 63,568 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Shalini Sharp sold 1,106 shares of Neurocrine Biosciences stock in a transaction on Friday, May 17th. The stock was sold at an average price of $141.90, for a total transaction of $156,941.40. Following the completion of the transaction, the director now directly owns 994 shares of the company’s stock, valued at $141,048.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Shalini Sharp sold 1,106 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $141.90, for a total value of $156,941.40. Following the completion of the transaction, the director now owns 994 shares in the company, valued at $141,048.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $135.51, for a total value of $36,994.23. Following the completion of the transaction, the insider now directly owns 7,507 shares in the company, valued at $1,017,273.57. The disclosure for this sale can be found here. Insiders have sold a total of 180,770 shares of company stock valued at $25,047,308 over the last three months. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

NBIX has been the subject of several research reports. Barclays raised their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research report on Thursday, May 2nd. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Citigroup raised their price objective on Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Finally, Mizuho lifted their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $148.96.

View Our Latest Stock Analysis on NBIX

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded down $1.11 during midday trading on Friday, hitting $139.40. The company had a trading volume of 423,935 shares, compared to its average volume of 730,788. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $148.37. The business’s 50 day simple moving average is $138.66 and its two-hundred day simple moving average is $131.98. The stock has a market cap of $14.03 billion, a PE ratio of 38.40 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The company had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.17 EPS for the current fiscal year.

About Neurocrine Biosciences

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Further Reading

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.